Capricor nabs accelerated review status in U.S. for Duchenne candidate CAP-1002; shares up 9% premarket [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
Capricor nabs accelerated review status in U.S. for Duchenne candidate CAP-1002; shares up 9% premarketCapricor Therapeutics (NASDAQ:CAPR) is up9% premarket on modestly higher volume in response to itsannouncement that the FDA has designated Duchenne muscular dystrophy (DMD) candidate CAP-1002 a Regenerative Medicine Advanced Therapy (RMAT).RMAT is the same as Breakthrough Therapy status for drugs. It provides for more frequent interactions with the FDA, priority review and accelerated approval.A registration study, HOPE-2, is about to start enrollment.CAP-1002 is an investigational allogeneic, off-the-shelf cardiac cell therapy derived from donor heart tissue and infused directly into the patient's coronary artery via a catheter.See all stocks on the move »Now read:Teva: Is This What A Bloodbath Looks Like? »
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Edgewise gets EU orphan drug status for muscular dystrophy drug [Seeking Alpha]Seeking Alpha
- Thinking about buying stock in Curiositystream, Capricor Therapeutics, PowerFleet, Absci, or Nano-X Imaging?PR Newswire
- Capricor Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- Earnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 2/29/24 - Beat
CAPR
Analyst Actions
- 3/1/24 - HC Wainwright
CAPR
Sec Filings
- 4/1/24 - Form ARS
- 4/1/24 - Form DEF
- 3/20/24 - Form PRE
- CAPR's page on the SEC website